Cargando…
Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study
| Autores principales: | , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6087720/ https://www.ncbi.nlm.nih.gov/pubmed/29572505 http://dx.doi.org/10.1038/s41375-018-0023-2 |
| _version_ | 1783346726205128704 |
|---|---|
| author | Rule, S Jurczak, W Jerkeman, M Rusconi, C Trneny, M Offner, F Caballero, D Joao, C Witzens-Harig, M Hess, G Bence-Bruckler, I Cho, S-G Thieblemont, C Zhou, W Henninger, T Goldberg, J Vermeulen, J Dreyling, M |
| author_facet | Rule, S Jurczak, W Jerkeman, M Rusconi, C Trneny, M Offner, F Caballero, D Joao, C Witzens-Harig, M Hess, G Bence-Bruckler, I Cho, S-G Thieblemont, C Zhou, W Henninger, T Goldberg, J Vermeulen, J Dreyling, M |
| author_sort | Rule, S |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-6087720 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2018 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-60877202018-08-14 Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study Rule, S Jurczak, W Jerkeman, M Rusconi, C Trneny, M Offner, F Caballero, D Joao, C Witzens-Harig, M Hess, G Bence-Bruckler, I Cho, S-G Thieblemont, C Zhou, W Henninger, T Goldberg, J Vermeulen, J Dreyling, M Leukemia Brief Communication Nature Publishing Group UK 2018-02-02 2018 /pmc/articles/PMC6087720/ /pubmed/29572505 http://dx.doi.org/10.1038/s41375-018-0023-2 Text en © The Author(s) 2018 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
| spellingShingle | Brief Communication Rule, S Jurczak, W Jerkeman, M Rusconi, C Trneny, M Offner, F Caballero, D Joao, C Witzens-Harig, M Hess, G Bence-Bruckler, I Cho, S-G Thieblemont, C Zhou, W Henninger, T Goldberg, J Vermeulen, J Dreyling, M Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study |
| title | Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study |
| title_full | Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study |
| title_fullStr | Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study |
| title_full_unstemmed | Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study |
| title_short | Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study |
| title_sort | ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label ray study |
| topic | Brief Communication |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6087720/ https://www.ncbi.nlm.nih.gov/pubmed/29572505 http://dx.doi.org/10.1038/s41375-018-0023-2 |
| work_keys_str_mv | AT rules ibrutinibversustemsirolimus3yearfollowupofpatientswithpreviouslytreatedmantlecelllymphomafromthephase3internationalrandomizedopenlabelraystudy AT jurczakw ibrutinibversustemsirolimus3yearfollowupofpatientswithpreviouslytreatedmantlecelllymphomafromthephase3internationalrandomizedopenlabelraystudy AT jerkemanm ibrutinibversustemsirolimus3yearfollowupofpatientswithpreviouslytreatedmantlecelllymphomafromthephase3internationalrandomizedopenlabelraystudy AT rusconic ibrutinibversustemsirolimus3yearfollowupofpatientswithpreviouslytreatedmantlecelllymphomafromthephase3internationalrandomizedopenlabelraystudy AT trnenym ibrutinibversustemsirolimus3yearfollowupofpatientswithpreviouslytreatedmantlecelllymphomafromthephase3internationalrandomizedopenlabelraystudy AT offnerf ibrutinibversustemsirolimus3yearfollowupofpatientswithpreviouslytreatedmantlecelllymphomafromthephase3internationalrandomizedopenlabelraystudy AT caballerod ibrutinibversustemsirolimus3yearfollowupofpatientswithpreviouslytreatedmantlecelllymphomafromthephase3internationalrandomizedopenlabelraystudy AT joaoc ibrutinibversustemsirolimus3yearfollowupofpatientswithpreviouslytreatedmantlecelllymphomafromthephase3internationalrandomizedopenlabelraystudy AT witzensharigm ibrutinibversustemsirolimus3yearfollowupofpatientswithpreviouslytreatedmantlecelllymphomafromthephase3internationalrandomizedopenlabelraystudy AT hessg ibrutinibversustemsirolimus3yearfollowupofpatientswithpreviouslytreatedmantlecelllymphomafromthephase3internationalrandomizedopenlabelraystudy AT bencebruckleri ibrutinibversustemsirolimus3yearfollowupofpatientswithpreviouslytreatedmantlecelllymphomafromthephase3internationalrandomizedopenlabelraystudy AT chosg ibrutinibversustemsirolimus3yearfollowupofpatientswithpreviouslytreatedmantlecelllymphomafromthephase3internationalrandomizedopenlabelraystudy AT thieblemontc ibrutinibversustemsirolimus3yearfollowupofpatientswithpreviouslytreatedmantlecelllymphomafromthephase3internationalrandomizedopenlabelraystudy AT zhouw ibrutinibversustemsirolimus3yearfollowupofpatientswithpreviouslytreatedmantlecelllymphomafromthephase3internationalrandomizedopenlabelraystudy AT henningert ibrutinibversustemsirolimus3yearfollowupofpatientswithpreviouslytreatedmantlecelllymphomafromthephase3internationalrandomizedopenlabelraystudy AT goldbergj ibrutinibversustemsirolimus3yearfollowupofpatientswithpreviouslytreatedmantlecelllymphomafromthephase3internationalrandomizedopenlabelraystudy AT vermeulenj ibrutinibversustemsirolimus3yearfollowupofpatientswithpreviouslytreatedmantlecelllymphomafromthephase3internationalrandomizedopenlabelraystudy AT dreylingm ibrutinibversustemsirolimus3yearfollowupofpatientswithpreviouslytreatedmantlecelllymphomafromthephase3internationalrandomizedopenlabelraystudy |